Curaleaf (CURA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
9 Aug, 2026Executive summary
Achieved Q2 2026 revenue of $340 million, up 10% year-over-year, surpassing guidance and internal projections, with adjusted EBITDA of $70 million (21% margin) and net income from continuing operations of $12.5 million.
International revenue grew 26% year-over-year to $51 million, led by Germany, UK, and Poland, with expansion into Turkey, France, and Spain expected in 2027.
Domestic segment grew 7% year-over-year, with broad-based growth in Ohio, Utah, New York, Florida, and Maryland.
Gross margin reached 50% (adjusted gross margin 50.2%), and adjusted EBITDA margin was 21%, despite international drag.
Strong operational execution, improved cultivation, and brand strength drove results, with strategic priorities on product quality, supply chain, and customer experience.
Financial highlights
Q2 2026 revenue: $340 million, up 10% year-over-year and 5% sequentially; adjusted EBITDA: $70 million (21% margin); net income per share was $0.05.
Gross profit was $170 million (50% margin), with adjusted gross profit of $171 million (50.2% margin).
Cash balance as of June 30, 2026: $107 million; total debt: $612 million; debt to trailing twelve months adjusted EBITDA ratio: 2.3x.
Operating cash flow was $29 million in Q2; free cash flow $13 million; six-month net revenue was $664.3 million, with net income of $82.6 million.
Retail/wholesale revenue mix was 71%/28%.
Outlook and guidance
Q3 revenue expected to increase low single digits sequentially, implying ~$347 million, with continued momentum in domestic and international markets.
Multiple catalysts expected in 2026 and beyond to expand profitability and increase cash generation.
Anticipates continued strong traffic growth, mindful of macro volatility, energy costs, and interest rates.
Expects margin expansion and improved cash flow from cost reduction and inventory management initiatives.
Anticipated launches in Turkey, France, and Spain in 2027 to drive long-term international growth.
Latest events from Curaleaf
- All resolutions, including U.S. continuation and board elections, were approved without dissent.CURA
AGM 2026 - Q1 2026 revenue rose 6% to $324M, with $70M net income and strong global expansion.CURA
Q1 2026 - Q4 2025 revenue hit $333M, margins improved, and international revenue grew 65% year-over-year.CURA
Q4 2025 - Six directors elected, board set at 10, and auditor appointed with no shareholder questions.CURA
AGM 2025 - Q3 revenue hit $320M, with 56% international growth and improved margins despite price pressure.CURA
Q3 2025 - Q3 saw $331M revenue, 49% gross margin, and 82% international growth amid U.S. headwinds.CURA
Q3 2024 - Q2 revenue up 2% to $342M, with 78% international growth and 48% adjusted gross margin.CURA
Q2 2024 - Board size set at 10, all directors and auditor approved, with no questions from shareholders.CURA
AGM 2024 - 2024 revenue flat at $1.34B; international sales up 73% and margins improved.CURA
Q4 2024